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OBJECTIVE—Berardinelli-Seip congenital lipodystrophy type 2
(BSCL2) is a recessive disorder featuring near complete absence
of adipose tissue. Remarkably, although the causative gene,
BSCL2, has been known for several years, its molecular function
and its role in adipose tissue development have not been
elucidated. Therefore, we examined whether BSCL2 is involved
in the regulation of adipocyte differentiation and the mechanism
whereby pathogenic mutations in BSCL2 cause lipodystrophy.
RESEARCH DESIGN AND METHODS—Following the char-
acterization of BSCL2 expression in developing adipocytes,
C3H10T1/2 mesenchymal stem cells were generated in which
BSCL2 expression was knocked down using short hairpin RNA
(shRNA). These cells were used to investigate whether BSCL2 is
required for adipogenesis. BSCL2 constructs harboring patho-
genic mutations known to cause lipodystrophy were also gener-
ated and characterized.
RESULTS—BSCL2 expression was strongly induced during
adipocyte differentiation, and the induction of BSCL2 expression
was essential for adipogenesis to occur. The initial induction of
key adipogenic transcription factors, including peroxisome pro-
liferator–activated receptor (PPAR) and CAAT/enhancer-
binding protein-, was preserved in cells lacking BSCL2.
However, the expression of these critical factors was not sus-
tained, suggesting that the activity of PPAR was impaired.
Moreover, expression of key genes mediating triglyceride syn-
thesis, including AGPAT2, lipin 1, and DGAT2, was persistently
reduced and lipid accumulation was inhibited. Analysis of patho-
genic missense mutants of BSCL2 revealed that the amino acid
substitution A212P causes aberrant targeting of BSCL2 within
the cell, suggesting that subcellular localization of BSCL2 may be
critical to its function.
CONCLUSIONS—This study demonstrates that BSCL2 is an
essential, cell-autonomous regulator of adipogenesis. Diabetes
57:2055–2060, 2008
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etabolic homeostasis requires the ability to
expand adipose tissue appropriately, as illus-
trated by lipodystrophy, in which inability to
increase adipose tissue mass commonly leads
to severe hypertriglyceridemia, insulin resistance, and
diabetes due to ectopic lipid accumulation in other tissues
(1). Identifying the key genes and regulatory processes
involved in adipocyte development is likely to enhance
understanding of both pathologically increased and de-
creased adipose mass.
Several different genetic defects in human lipodystrophy
have been identiﬁed. Some affect genes with a well-
established role in adipogenesis or lipid metabolism, such
as PPARG, AKT2, and l-acylglycerol-3-phosphate 0-acyl-
transferate2 (AGPAT2) (1). The role of others, such as
LMNA and ZMPSTE, is less clear, although defects in
LMNA do perturb adipocyte differentiation in a cell-auton-
omous manner (2). In contrast, although mutations in
BSCL2 produce more severe adipose tissue loss than any
of these other genetic defects, very little is known about
the underlying pathogenic mechanism (3,4). The global
adipose deﬁcit in affected individuals has led to specula-
tion that BSCL2 is involved in stem cell determination
toward the adipogenic lineage (5). An alternative sugges-
tion, based on reports of relatively high expression in the
central nervous system, is that lipodystrophy results from
loss of a key central function of BSCL2 (3–6). A recent
study has described abnormal lipid droplet formation in
yeast lacking the BSCL2 orthologue, YLR404W, and a
similar defect in ﬁbroblasts isolated from a BSCL2-deﬁ-
cient patient (7). However, the localization and function of
BSCL2 in differentiating or mature adipocytes remains to
be elucidated, as does the molecular mechanism whereby
BSCL2 mutations cause lipodystrophy.
RESEARCH DESIGN AND METHODS
Tissue analysis. Tissues were isolated from 10-week-old male C57Bl6 mice, and
RNA was isolated using STAT-60 (AMS Biotechnology). RNA was quantiﬁed and
reverse transcribed as previously described (8). Murine and human adipose tissue
were isolated and fractionated, also as previously described (9).
Cell culture. C3H10T1/2 mesenchymal cells were grown in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) containing 10% newborn calf serum. Two
days after reaching conﬂuence, cultures were induced to differentiate in
DMEM (5 mmol/l glucose) containing 10% FCS, supplemented with 1 mol/l
insulin, 0.5 mmol/l 3-isobutyl-1-methyl-xanthine, and 1 mol/l dexamethasone
for 2 days and then supplemented with 1 mol/l insulin alone for 2 days. After
4 days, cells were cultured in DMEM containing 10% FCS. Human and murine
cells from the stromovascular fraction of adipose tissue were prepared,
cultured, and differentiated as previously described (8). RNA isolation, reverse
transcription, and real-time PCR were performed, also as previously described
(8). RNA was isolated and reverse transcribed from transiently transfected
cells using the Qantitect Reverse Transcription kit (Qiagen).
E14 murine embryonic stem cells culture, embryoid body formation, and
adherent culture were performed as previously described (10). Adipogenesis
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FIG. 1. BSCL2 expression in adipose
tissue and developing and mature
adipocytes. A: BSCL2 mRNA expres-
sion was determined by real-time
PCR in subcutaneous (scW) and ep-
ididymal (epW) white adipose tis-
sue, brown adipose tissue (BAT),
brain (Brn), skeletal muscle (SkM),
heart (Hrt), liver (Lvr), kidney
(Kdy), lung (Lng), and spleen (Spln)
isolated from 6-week-old male mice.
Data are normalized to 18S RNA and
represent the means  SEM (n  4).
BSCL2 mRNA expression was as-
sayed by real-time PCR in differenti-
ating cultures of murine embryonic
stem cell embryoid bodies (B),
C3H10T1/2 cells (C), and murine
(D) or human (E) preadipocytes
isolated from the stromovascular
fraction of adipose tissue. Data
represents means  SEM of four
(B), three (C), or six (E) indepen-
dent experiments. In D, data are
means  SD obtained in two time
courses with cells pooled from
three mice in each case. *Statisti-
cally signiﬁcant difference from
values at day 0 (P < 0.05). BSCL2
mRNA expression was also deter-
mined in mature adipocyte (MAd)
and stromovascular (SV) fractions
from collagenase-digested mouse
(F) or human (G) adipose tissue.
Data are means  SEM from 5 mice
(F) and 11 individuals (G). *Signif-
icant difference vs. expression in
mature adipocyte fraction (P <
0.05). H: C3H10T1/2 cells stably
transfected with myc-tagged wild-
type BSCL2 were induced to differ-
entiate for 6 days, permeablized
with 0.05% saponin, and then ﬁxed
and immunostained with anti-myc
(BSCL2) and anti-calnexin anti-
bodies. Merged image shows over-
lay of the two proteins in which
yellow indicates colocalization.
White arrows indicate areas of co-
localization, and the inset shows a
close-up of one such area. Scale
bar  20 m. (Please see http://
dx.doi.org/10.2337/db08-0184 for a
high-quality digital representation
of this ﬁgure.)
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adipocytes. Oil red O staining of lipid accumulation was performed as
previously described (8).
Retrovirus-mediated short hairpin RNA knockdown. Two short hairpin
RNA (shRNA) sequences targeting BSCL2 were designed and cloned into the
RNAi-Ready pSIREN-RetroQ vector (BD Biosciences Clontech). Retroviral
packaging BOSC-HEK293 cells were transfected with both these constructs
and a control shRNA vector to generate retroviruses to infect C3H10T1/2 cells.
Virus collection, preparation, and cell infection were performed as previously
described (9).
Western blotting and immunoﬂuorescence. Protein samples were pre-
pared as previously described (8). A total of 30 g protein was denatured and
analyzed by Western blotting, using antibodies to C/EBP, C/EBP, and ETO
(Santa Cruz Biotechnology); myc (4G10, UBI); and calnexin (AbCam). For
immunoﬂuorescence studies, cells were grown on glass coverslips, ﬁxed in
10% formalin, permeablized with 0.5% saponin, blocked with 1% BSA, and
probed with antibodies diluted in 1% BSA. Coverslips were mounted in
ProLong Gold medium (Invitrogen) and analyzed on a Zeiss 510 Meta confocal
microscope.
RESULTS
Previous studies reporting the tissue distribution of
BSCL2, as assessed by Northern blotting, have reported
highest expression in the brain (4) or did not determine
adipose tissue expression (11). Quantiﬁcation of BSCL2
using real-time PCR in a range of mouse tissues demon-
strated that expression was highest in subcutaneous and
epididymal white adipose depots and interscapular brown
adipose tissue (Fig. 1A). Expression in whole brain was
20–35% that in adipose tissue, leading us to speculate
that BSCL2 mutations may cause lipodystrophy via direct
effects in adipose tissue.
To examine the earliest stages of cell commitment to the
adipocyte lineage, we investigated the expression of
BSCL2 in murine embryonic stem cell embryoid bodies
during differentiation to adipocytes. Treatment with adi-
pogenic medium increased BSCL2 expression in these
cells within 24 h, and expression continued to rise as the
number of adipocytes increased (Fig. 1B). The time course
of induction was similar to that of the key adipocyte
markers PPAR2 and C/EBP (Figs. S1A and B [available
in an online appendix at http://dx.doi.org/10.2337/db08-
0184]), suggesting a role for BSCL2 in terminal adipocyte
differentiation rather than early stem cell commitment.
Consistent with this ﬁnding, adipogenic induction of
C3H10T1/2 mesenchymal cells signiﬁcantly increased
BSCL2 expression, apparent after 24 h and strongly in-
duced after 3 days (Fig. 1C). Again, this pattern of expres-
sion was similar to that of PPAR2 and C/EBP (Fig. S1C
and D). A similar, albeit delayed, induction of BSCL2
expression also occurs in differentiating 3T3-L1 preadipo-
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FIG. 2. Effect of BSCL2 knockdown on adipogenesis in C3H10T1/2 pluripotent stem cells. A: BSCL2 mRNA was assayed by real-time PCR in
C3H10T1/2 cells stably infected with a retrovirus generated with control shRNA vector (black bars) or BSCL2 targetting shRNA1 (dark gray bars)
or shRNA2 (light gray bars). Values are normalized to cyclophilin A expression. Data are means  SEM (n  4). *Statistically signiﬁcant
difference vs. control cells at the same time point. B: Control cells or cells expressing BSCL2 targetting shRNA1 or shRNA2 were differentiated
for 8 days, and lipid accumulation was assessed by oil red O (upper panel) and light microscopy (lower panel). Expression of mRNA encoding
adipocyte transcription factors (C) and mature adipocyte marker proteins (D) was assayed by real-time PCR in control cells at day 0 (white bars)
and following differentiation for 8 days in control cells (black bars) or cells expressing BSCL2 targetting shRNA1 (dark gray bars) or shRNA2
(light gray bars). Values are normalized to cyclophilin A expression. Data are means  SEM (n  4). *Statistically signiﬁcant difference vs.
control cells at day 8 (black bars). (Please see http://dx.doi.org/10.2337/db08-0184 for a high-quality digital representation of this ﬁgure.)
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of differentiation. BSCL2 mRNA expression was also in-
duced in differentiating isolated primary mouse (Fig. 1D)
and human (Fig. 1E) preadipocytes, remaining raised in
the mature adipocytes. Moreover, BSCL2 mRNA was most
abundant in the mature adipocyte rather than in stem
cell/preadipocyte-containing stromovascular fraction of
both mouse (Fig. 1F) and human (Fig. 1G) adipose tissue.
These data collectively suggest a role for BSCL2 in devel-
oping adipocytes rather than in preadipocytes or stem
cells.
Previous studies have demonstrated that BSCL2 is lo-
calized in the endoplasmic reticulum in nonadipogenic cell
lines (11,12) and that BSCL2 is inserted in the endoplasmic
reticulum membrane (13). Next, we generated C3H10T1/2
cells stably expressing myc-tagged BSCL2. Following dif-
ferentiation to adipocytes, BSCL2 was found to be also
mainly colocalized with the endoplasmic reticulum mem-
brane protein calnexin (Fig. 1H). Similar colocalization
was also observed with the endoplasmic reticulum marker
calreticulin (data not shown), demonstrating that the major-
ity of BSCL2 is found in this compartment in adipocytes.
To test the importance of BSCL2 in developing adipo-
cytes, we generated two C3H10T1/2 cell lines stably ex-
pressing shRNA species targeting BSCL2. Real-time PCR
revealed that both BSCL2 shRNAs effectively inhibited the
expression of BSCL2 (Fig. 2A). Following differentiation
for 8 days, lipid accumulation was severely impaired in
cells lacking BSCL2 (Fig. 2B), as was the induction of
the adipogenic transcription factors C/EBP, PPAR1,
PPAR2, and sterol regulatory element binding protein-1c
(SREBP1c) (Fig. 2C). These cells also had signiﬁcantly
reduced expression of GLUT4, diacylglycerol O-acyltrans-
ferase 2 (DGAT2), lipoprotein lipase, and aP2 (Fig. 2D),
demonstrating that the induction of BSCL2 is important
for normal adipogenesis.
The induction and activation of C/EBP and C/EBP are
the best-characterized early events in adipogenesis and are
critical for the subsequent induction of the central regula-
tors of this process, C/EBP and PPAR (14). When
BSCL2 knockdown cells were induced to differentiate for
various times up to 72 h, the induction of C/EBP and
C/EBP mRNA (Figs. 3A and B, respectively) and protein
(Fig. 3C) was equivalent to that in control cells. The rapid
suppression of ETO, an inhibitor of C/EBP (9), was also
normal in cells lacking BSCL2 (Fig. 3C). Despite the
decreased expression of C/EBP and PPAR2 mRNAs at
later time points (Fig. 2C), the early induction of these
factors was also not consistently reduced by loss of
BSCL2 expression (Fig. 3D and E). In contrast, the expres-
sion of RNA encoding SREBP1c was dramatically de-
creased in cells lacking BSCL2 at the same time points
(Fig. 3F), as was the expression of key enzymes of
triglyceride synthesis, AGPAT2 (Fig. 3G), DGAT2 (Fig.
3H), and lipin 1 (Fig. 3I).
Having examined how BSCL2 loss results in a failure of
adipogenesis, we examined how pathogenic mutations in
BSCL2 may result in the loss of its functional activity. The
majority of mutations in BSCL2 causing lipodystrophy
generate very short or mostly nonsense proteins (6). This,
together with the recessive inheritance pattern, indicates
that complete loss of BSCL2 function is required for the
development of lipodystrophy. The longest reported pre-
mature stop mutation, R275X, is truncated just after the
second transmembrane domain, resulting in a predicted
protein lacking only the COOH-terminal cytoplasmic tail
(4,15). In addition, one lipodystrophy-associated missense
mutation has been described, causing substitution of ala-
nine at codon 212 for proline (4). Cells were transiently
transfected with constructs encoding either wild-type,
R275X, or A212P human BSCL2. Real-time PCR detecting
human BSCL2 mRNA in this murine cell line revealed
similar transcript levels of wild-type, R275X, and A212P
BSCL2 (Fig. 4A). When lysates from identically treated
cells were Western blotted for the transfected proteins,
0
50
100
150
200
250
0 2 4 8 24 72
0
50
100
150
200
250
0 2 4 8 24 72
C/EBPβ C/EBPδ
Differentiation (h) Differentiation (h)
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
 
(
A
U
)
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
 
(
A
U
) A
C
*
*
*
*
0
100
200
300
0 4 24 72
C/EBPα
Differentiation (h)
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
 
(
A
U
)
D
*
* *
0
100
200
300
04 2 4 7 2
PPARγ2
Differentiation (h)
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
 
(
A
U
) E
0
200
400
600
800
0 4 24 72
F
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
 
(
A
U
)
Differentiation (h)
SREBP1c
** * * * * **
0
200
400
600
800
0 4 24 72
AGPAT2
Differentiation (h)
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
 
(
A
U
) G
* *
* *
0
100
200
300
400
0 4 24 72
DGAT2
Differentiation (h)
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
 
(
A
U
)
* * * *
H
C/EBP?
C/EBP?
ETO
CalNex
c12c12 c12c12
0h 4h 24h 72h Diff’ (h)
C/EBPβ
C/EBPδ
ETO
CalNex
c12c12 c12c12
0h 4h 24h 72h Diff’ (h)
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
 
(
A
U
) I
0
100
200
300
0 4 24 72
Lipin 1β
Differentiation (h)
* * *
B
FIG. 3. BSCL2 knockdown does not inhibit the induction of C/EBP,
C/EBP C/EBP, or PPAR but inhibits SREBP1c and lipogenic gene
expression during early adipogenesis in C3H10T1/2 stem cells. Control
cells (black bars) or cells expressing BSCL2 targetting shRNA1 (dark
gray bars) or shRNA2 (light gray bars) were induced to differentiate
for various times, and the expression of mRNA encoding C/EBP (A)
and C/EBP (B) was determined by real-time PCR. Data are means 
SEM (n  4). *Statistically signiﬁcant difference vs. control cells at the
same time point. C: Control cells (c) or cells expressing BSCL2
targetting shRNA1 (1) or shRNA2 (2) were differentiated for various
times and lysed, and samples were Western blotted to determine the
expression of C/EBP, C/EBP, ETO, and calnexin as indicated. Con-
trol cells (black bars) or cells expressing BSCL2 targetting shRNA1
(dark gray bars) or shRNA2 (light gray bars) were induced to differ-
entiate, and the expression of mRNA encoding C/EBP (D), PPAR2
(E), SREBP1c (F), AGPAT2 (G), DGAT2 (H), and lipin 1 (I) was
determined by real-time PCR. Data are means  SEM (n  4).
*Statistically signiﬁcant difference vs. control cells at the same time
point. Data were normalized to cyclophilin A mRNA expression.
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plex (Fig. 4B). The severely impaired mobility of BSCL2 on
SDS-PAGE may result from aggregation due to hydropho-
bicity of this transmembrane protein and is consistent
with previous studies in which the majority of BSCL2 runs
at a molecular weight of 250 kDa (12). While both wild-
type and A212P proteins were clearly detectable, the
R275X protein was not, strongly suggesting that the pro-
tein is either rapidly degraded or not translated. When
assessed by immunoﬂuorescence, we found that, unlike
wild-type BSCL2, a substantial proportion of A212P-BSCL2
was localized to the nuclear envelope (Fig. 4C). Consistent
with our Western blot data, R275X-BSCL2 was undetect-
able by immunoﬂuorescence (data not shown).
DISCUSSION
We show that BSCL2 expression is critical for normal
adipogenesis to occur in vitro. The recent demonstration
that loss of BSCL2 causes a defect of lipid droplet mor-
phology led the authors to suggest that defective lipid
droplet formation is the primary cause of BSCL2 disease
(7). We show that cells lacking BSCL2 fail to induce the
expression of SREBP1c and the lipogenic enzymes
AGPAT2, DGAT2, and lipin 1. This is evident within 24 h
of the induction of adipogenesis, before lipid droplets
usually form in these cells. Thus, we propose that a
failure to induce adipogenic transcriptional events
makes a major contribution to the development of this
phenotype.
The failure to maintain PPAR expression in BSCL2
knockdown cells during the later stages of adipogenesis is
consistent with reports that loss of either AGPAT2 or lipin
1 inhibits adipogenic gene expression and triglyceride
synthesis (16–18). Loss of AGPAT2 activity causes lipo-
dystrophy in humans (BSCL type 1), and lipin 1 disruption
causes lipodystrophy in the ﬂd mouse (19,20). Moreover,
DGAT2-deﬁcient mice suffer severe lipopenia (21). Our
data strongly suggest that individuals lacking BSCL2 may
fail to induce the expression of these key lipogenic en-
zymes during adipogenesis in vivo, which may explain a
phenotype more severe than that associated with loss of
AGPAT2 alone.
Failure to induce SREBP1c expression in cells lacking
BSCL2 may compound, or perhaps cause, these gene-
expression changes. SREBP1c both directly activates tran-
scription of adipogenic genes and enhances production of
an endogenous ligand for PPAR (14,22,23). The early
induction of PPAR and C/EBP in BSCL2 knockdown
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C/EBP, which are unaffected by loss of BSCL2 (Fig. 3).
However, PPAR normally acts to sustain the expression
of PPAR and C/EBP in the maturing adipocyte. Hence,
loss of SREBP1c-dependent PPAR ligand production may
contribute to decreased PPAR and C/EBP expression in
maturing adipocytes lacking BSCL2.
Our data also give novel insight into the mechanism
linking two BSCL2 mutants to generalized lipodystrophy.
First, the truncated R275X protein is not expressed in
cells, suggesting that individuals homozygous for this
mutation may be effectively null for BSCL2 expression.
Second, the A212P mutant of BSCL2 exhibits aberrant
accumulation in the nuclear envelope. The failure of this
mutant to support adipose tissue formation in vivo
strongly implies that it is functionally inactive. Given
the critical importance of this residue, this mutant may
be particularly useful in future mechanistic studies of
BSCL2 function.
These data demonstrate that BSCL2 plays an important
role in the development of mature adipocytes and strongly
suggest that the nearly global lack of adipose tissue in
patients with BSCL2 mutations is a consequence of a
cell-autonomous defect of adipogenesis. This provides the
ﬁrst mechanistic insight into how BSCL2 mutations cause
severe lipodystrophy.
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